National Institutes of Technology

Astec Appoints New Members to Board of Directors

Retrieved on: 
Tuesday, November 8, 2022

CHATTANOOGA, Tenn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Astec Industries, Inc. (Nasdaq: ASTE) announced the companys board of directors (the Board) elected Mr. Mark Gliebe and Mr. Nalin Jain, each a new independent director, effective as of November 10, 2022.

Key Points: 
  • CHATTANOOGA, Tenn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Astec Industries, Inc. (Nasdaq: ASTE) announced the companys board of directors (the Board) elected Mr. Mark Gliebe and Mr. Nalin Jain, each a new independent director, effective as of November 10, 2022.
  • The election of Mr. Gliebe and Mr. Jain increases the size of the Board to 12 directors, 11 of whom are independent directors.
  • Each of Mr. Gliebe and Mr. Jain will serve as a member of the Audit Committee of the Board.
  • William Gehl, Chairman of Astecs Board of Directors, said, We are pleased to welcome Mark and Nalin to the Board.

Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Training Ship OSHIMA MARU Built for Oshima College

Retrieved on: 
Thursday, October 13, 2022

TOKYO, Oct 13, 2022 - (JCN Newswire) - Mitsubishi Shipbuilding Co., Ltd., a Mitsubishi Heavy Industries (MHI) Group company based in Yokohama, today held a christening and launch ceremony for the OSHIMA MARU, a training ship for National Institute of Technology (Kosen), Oshima College.

Key Points: 
  • TOKYO, Oct 13, 2022 - (JCN Newswire) - Mitsubishi Shipbuilding Co., Ltd., a Mitsubishi Heavy Industries (MHI) Group company based in Yokohama, today held a christening and launch ceremony for the OSHIMA MARU, a training ship for National Institute of Technology (Kosen), Oshima College.
  • The ceremony took place at the Enoura Plant at MHI's Shimonoseki Shipyard & Machinery Works in Yamaguchi Prefecture.
  • The OSHIMA MARU is the fourth-generation training vessel for the school, and the first new ship in 29 years, since 1993.
  • This is the second vessel Mitsubishi Shipbuilding has built for the school, following the third-generation training ship currently in operation.

Time for Change in NASH: How Non-Invasive Biomarkers are Driving a Paradigm Shift in Clinical Trials and Clinical Care, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 12, 2022

TORONTO, Oct. 12, 2022 /PRNewswire-PRWeb/ -- Diagnosing and assessing the progression of nonalcoholic steatohepatitis (NASH) continue to be some of the most challenging aspects of its management. Most patients would opt out of the diagnostic or follow-up liver biopsy. Also, liver biopsies would not be a front-line test offered by primary care physicians, endocrinologists and diabetologists where a large proportion of undiagnosed patients exist. In addition, recent clinical trial data has shown considerable variability in histopathology readings, making it unreliable for use in clinical trials.

Key Points: 
  • In this free webinar, learn how non-invasive biomarkers are driving a paradigm shift in nonalcoholic steatohepatitis (NASH) clinical trials and clinical care.
  • The speakers will discuss emerging NITs for use in both clinical trials and clinical care.
  • Register to learn how non-invasive biomarkers are driving a paradigm shift in NASH clinical trials and clinical care.
  • For more information, or to register for this event, visit Time for Change in NASH: How Non-Invasive Biomarkers are Driving a Paradigm Shift in Clinical Trials and Clinical Care .

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)

Retrieved on: 
Thursday, September 29, 2022

These interim results report findings regarding the effects of AXA1125 administration on selected outcome measures after 12- and 24-weeks of treatment.

Key Points: 
  • These interim results report findings regarding the effects of AXA1125 administration on selected outcome measures after 12- and 24-weeks of treatment.
  • Specifically, the study examines liver stiffness, changes of which have been correlated with improvements in liver fibrosis and outcomes in clinical studies.
  • Study participants were randomized 1:1:1 to receive either a placebo or 22.6g or 33.9g of AXA1125 twice daily.
  • Axcellas pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and non-alcoholic steatohepatitis (NASH).

Bloomreach Appoints Anirban Bardalaye as Chief Product Officer

Retrieved on: 
Tuesday, September 13, 2022

MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Bloomreach, the world's #1 Commerce Experience Cloud, today announced it has appointed Anirban Bardalaye as Chief Product Officer, effective immediately. In this role, Anirban will further accelerate the growth of the company's three product pillars — Discovery, Engagement, and Content — as it continues to scale its Commerce Experience Cloud to serve businesses around the world. Anirban previously served as Vice President of Product Management, Commerce Cloud, at Salesforce, and in addition to his success as a Y Combinator-backed entrepreneur, has nearly 15 years of experience leading product strategy for SaaS companies. 

Key Points: 
  • With Extensive Experience in SaaS Product Leadership,
    MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Bloomreach , the world's #1 Commerce Experience Cloud, today announced it has appointed Anirban Bardalaye as Chief Product Officer, effective immediately.
  • "We're thrilled to have Anirban joining the team to lead Bloomreach into its next era of product leadership," said Raj De Datta, co-founder and CEO, Bloomreach.
  • "Bloomreach has made massive strides in product innovation these past few years alone, and now, it's poised to further redefine what an incredible commerce experience can achieve for businesses when driven by the right technology," said Anirban Bardalaye.
  • Anirban Bardalaye has served as Vice President of Product Management, Commerce Cloud, at Salesforce since 2019.

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, March 3, 2022

FOSTER CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2021 and corporate highlights.

Key Points: 
  • FOSTER CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2021 and corporate highlights.
  • We look forward to continuing our momentum with top-line data from the AVIATION trial of TERN-201 in NASH patients later this month.
  • Terns completed an upsized initial public offering in February 2021, raising $146.6 million in gross proceeds.
  • Net Loss: Net loss was $14.2 million and $50.2 million for the quarter and year ended December 31, 2021, respectively, as compared with $9.9 million and $40.6 million for the quarter and year ended December 31, 2020, respectively.

Viakoo Announces Exceptional Growth in 2021, Reaches One Billion Usage Hours

Retrieved on: 
Tuesday, February 8, 2022

MOUNTAIN VIEW, Calif., Feb. 8, 2022 /PRNewswire/ -- Viakoo, the leader in IoT vulnerability remediation, today announced exceptional growth in 2021 and continued momentum into 2022.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 8, 2022 /PRNewswire/ -- Viakoo, the leader in IoT vulnerability remediation, today announced exceptional growth in 2021 and continued momentum into 2022.
  • "Viakoo saw exceptional growth last year, as the company continued to gain traction protecting some of the largest organizations from ongoing cybersecurity threats facing IoT systems," said Bud Broomhead, CEO, Viakoo.
  • In 2021, Viakoo reached a milestone of over one billion usage hours, supporting over a million devices across hundreds of customers and thousands of users.
  • Earning extensive industry recognition and third-party validation, in 2021 Viakoo was named a Gartner Cool Vendor in Cyber-Physical Systems Security.

PAR Technology Expands Executive Team with New CPTO

Retrieved on: 
Tuesday, October 5, 2021

PAR Technology Corporation (PAR), a global restaurant technology company and provider of a unified commerce cloud platform for enterprise restaurants, today announced that Raju Malhotra has been named Chief Product & Technology Officer (CPTO)of PAR Technology Corporation.

Key Points: 
  • PAR Technology Corporation (PAR), a global restaurant technology company and provider of a unified commerce cloud platform for enterprise restaurants, today announced that Raju Malhotra has been named Chief Product & Technology Officer (CPTO)of PAR Technology Corporation.
  • Mr. Malhotra was formerly the CPTO at Punchh Inc., which was acquired by PAR in April 2021.
  • Rajus background is beyond impressive and in our short while working together, hes exceeded all expectations, said Savneet Singh, CEO of PAR Technology.
  • I am excited to join PAR Technology at this time of unprecedented growth in the hospitality industry.

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Retrieved on: 
Monday, August 2, 2021

Aramchol meglumine contains the same active pharmaceutical ingredient (API) called Aramchol.

Key Points: 
  • Aramchol meglumine contains the same active pharmaceutical ingredient (API) called Aramchol.
  • Exposure with once daily (QD) 383mg Aramchol meglumine oral dosage corresponds to that obtained with the existing twice daily (BID) 300mg Aramchol free acid form which is currently being evaluated in the Phase 3 ARMOR study.
  • This allows future development of the QD regimen with a potential improvement in convenience and adherence".
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

MobileDemand Launches Sleek and Powerful Rugged xTablet T1190

Retrieved on: 
Friday, July 16, 2021

CEDAR RAPIDS, Iowa, July 16, 2021 /PRNewswire-PRWeb/ --MobileDemand, provider of rugged tablets and mobile all-in-one computing solutions for enterprise productivity, today announced the launch of the xTablet T1190 as part of their portfolio of rugged xTablets.

Key Points: 
  • CEDAR RAPIDS, Iowa, July 16, 2021 /PRNewswire-PRWeb/ --MobileDemand, provider of rugged tablets and mobile all-in-one computing solutions for enterprise productivity, today announced the launch of the xTablet T1190 as part of their portfolio of rugged xTablets.
  • Soon-to-be Verizon LTE Certified, the xTablet T1190 will keep your workforce and fleet of devices connected and productive withstanding drops and reckless environments.
  • The xTablet T1190 brings convenience to customers and workers alike with its high resolution 10.1", 800-nits sunlight viewable, 10-point multi-touch display.
  • Available now, MobileDemand will showcase the thin and light xTablet T1190 at the RetailNOW conference July 25-27, 2021 in Nashville, TN, booth #310.